Research Highlights |
Featured
-
-
News |
Universities shun Europe's drug initiative
Intellectual-property rules push researchers away.
- Natasha Gilbert
-
Editorial |
The needs of the few
Developing drugs for rare diseases is a challenge that requires new regulatory flexibility.
-
News |
Russia pushes for domestic drug development
But building a complex industry from scratch won't be easy.
- Alla Katsnelson
-
Editorial |
Putting gender on the agenda
Biomedical research continues to use many more male subjects than females in both animal studies and human clinical trials. The unintended effect is to short-change women's health care.
-
News & Views |
Priming the antimalarial pipeline
Emerging resistance to existing antimalarial drugs could nullify efforts to eliminate this deadly disease. The discovery of thousands of agents active against malaria parasites offers hope for developing new drugs.
- David A. Fidock
-
News |
Biomarkers for kidney damage should speed drug development
Drug-safety indicators are the first fruits of a collaboration between academia, industry and regulators.
- Brendan Borrell
-
Research Highlights |
Drug development: Virus knockdown
-
Article |
Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte
To survive and evade host responses, malaria parasites export several hundred proteins into the host cell on infection. A feature of these proteins is a conserved, pentameric motif that is cleaved by an unknown protease before export. This is one of two independent studies revealing the identity of the protease as plasmepsin V, an aspartic acid protease located in the endoplasmic reticulum. This enzyme is essential for parasite viability and is an attractive candidate for drug development.
- Ilaria Russo
- , Shalon Babbitt
- & Daniel E. Goldberg
-
Article |
Retroviral intasome assembly and inhibition of DNA strand transfer
The integrase protein of retroviruses such as HIV-1 catalyses insertion of the viral genome into that of the host. Here, the long-awaited structure of the full-length integrase complex is predicted, revealing not only details of the biochemistry of the integration reaction, but also the means by which current inhibitors affect this process.
- Stephen Hare
- , Saumya Shree Gupta
- & Peter Cherepanov
-
Editorial |
Learning to share
By opening up its database of potential malaria drugs, GlaxoSmithKline has blazed a path that other pharmaceutical companies should follow.
-
News Feature |
Translational research: Talking up translation
Alan Ashworth took a cancer drug from Petri dish to patients in near record speed. Daniel Cressey meets a biologist who is evangelical about translational research.
- Daniel Cressey
-
News |
GlaxoSmithKline goes public with malaria data
Company to place structures and properties of drug leads in the public domain.
- Declan Butler